The stock of Neo Concept International Group Holdings Ltd (NCI) has gone up by 17.50% for the week, with a 37.87% rise in the past month and a 10.07% rise in the past quarter. The volatility ratio for the week is 9.23%, and the volatility levels for the past 30 days are 8.84% for NCI. The simple moving average for the past 20 days is 24.36% for NCI’s stock, with a -10.29% simple moving average for the past 200 days.
Is It Worth Investing in Neo Concept International Group Holdings Ltd (NASDAQ: NCI) Right Now?
Neo Concept International Group Holdings Ltd (NASDAQ: NCI) has a price-to-earnings ratio of 46.17x that is above its average ratio. Additionally, the 36-month beta value for NCI is -2.24. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NCI is 5.18M and currently, short sellers hold a 0.04% ratio of that float. The average trading volume of NCI on June 20, 2025 was 36.18K shares.
NCI) stock’s latest price update
Neo Concept International Group Holdings Ltd (NASDAQ: NCI)’s stock price has plunge by 17.50relation to previous closing price of 2.00. Nevertheless, the company has seen a 17.50% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-24 that Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK, April 24, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett’s Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the potential to substantially increase the market opportunity.
NCI Trading at 23.98% from the 50-Day Moving Average
After a stumble in the market that brought NCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NCI starting from Neo-concept (BVI) Ltd, who proposed sale 2,000,000 shares at the price of $0.68 back on Nov 15 ’24. After this action, Neo-concept (BVI) Ltd now owns shares of Neo Concept International Group Holdings Ltd, valued at $1,360,000 using the latest closing price.
Stock Fundamentals for NCI
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.2 for the gross margin
The net margin for Neo Concept International Group Holdings Ltd stands at 0.03. The total capital return value is set at 0.44.
Based on Neo Concept International Group Holdings Ltd (NCI), the company’s capital structure generated 1.05 points at debt to capital in total, while cash flow to debt ratio is standing at -0.9. The debt to equity ratio resting at -22.89. The interest coverage ratio of the stock is 1.57.
Currently, EBITDA for the company is 14.9 million with net debt to EBITDA at 3.27. When we switch over and look at the enterprise to sales, we see a ratio of 2.22. The receivables turnover for the company is 5.39for trailing twelve months and the total asset turnover is 1.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
In conclusion, Neo Concept International Group Holdings Ltd (NCI) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
